Jefferies raises Tarsus Pharmaceuticals price target on guidance
Jefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.
How this was made
The 30-second read
Why it matters
The analyst upgrade provides a fresh catalyst that could drive the stock higher despite broader market weakness.
Market read
Positive earnings and guidance lift for TARS amid a weak market may create a relative outperformance opportunity.
What to watch
Execution risk of Phase III assets and competition in rare‑disease space.
Background
Wall Street was down on Fed rate hike bets and oil prices; TARS stood out with a strong earnings beat and guidance lift.
Ticker impact
Jefferies raised its price target to $105 and highlighted raised Xdemvy 2026 guidance and recent Q2 earnings beat.
Potential short-term upside toward $105 target.
Target raise follows earnings beat and guidance lift, indicating improved outlook.
Market effects
Biotech sector may benefit from renewed investor interest after positive guidance.
US biotech stocks could see modest gains.
Limited to US-listed biotech investors.
Counterpoint
Target raise may be premature if pipeline risks materialize.
Key entities
- analystJefferies
Equity research firm that raised TARS price target.
- companyTarsus Pharmaceuticals
Biotech firm with raised Xdemvy guidance and Q2 earnings beat.
